BioCentury | Oct 16, 2006
Company News

Endo, RxKinetix deal

...ENDP said its Endo Pharmaceuticals Inc. subsidiary acquired drug delivery company RxKinetix for $20 million in...
...for $20 million in cash and up to $95 million in milestones. The deal includes RxKinetix's...
...severe pain in patients requiring continuous, 24-hour opioid treatment for an extended period of time. RxKinetix...
BioCentury | Mar 6, 2006
Clinical News

RK-0202: Phase II data

...tube compared to placebo (p=0.037). RX-0202 treated patients also had lower incidence of adverse events. RxKinetix Inc....
BioCentury | Mar 6, 2006
Clinical News

RK-0202: Phase III start

...RxKinetix will begin in the second half a double-blind, placebo-controlled Phase III trial. RxKinetix Inc. , Louisville...
BioCentury | Nov 7, 2005
Company News

Indian Immunologicals Ltd., RxKinetix deal

...RxKinetix will formulate using its ProJuvant vaccine delivery technology. Indian Immunologicals Ltd. , Hyderabad, India RxKinetix Inc....
BioCentury | Oct 24, 2005
Clinical News

RK-0202: Preliminary Phase II data

...safety issues, an independent data monitoring committee (IDMC) recommended stopping enrollment earlier in the trial. RxKinetix Inc....
BioCentury | Jun 9, 2003
Company News

Elan, RxKinetix deal

...and develop compound formulations to treat oral mucositis and other oral cavity diseases. As ended, RxKinetix...
...small molecule antioxidant formulated with RxKinetix's ProGelz polymer delivery system, is in Phase II testing. RxKinetix...
...restructuring and focusing on neurology, pain and autoimmune diseases. Elan Corp. plc (ELN), Dublin, Ireland RxKinetix Inc....
BioCentury | Jun 9, 2003
Product Development

Treating the treatments

...Corp. are placing their bets on growth factors to treat mucositis, while others, such as RxKinetix Inc....
...non-systemic approach. "There's absolutely no product out there right now," said Harry Ross, chairman of RxKinetix...
...end or the first quarter of 2004. RK-0202 is a small molecule antioxidant formulated with RxKinetix's...
BioCentury | Jan 27, 2003
Clinical News

RK-0202: Phase II

...placebo-controlled U.S. Phase II trial in 100 patients undergoing radiotherapy for head and neck cancer. RxKinetix Inc....
BioCentury | Jan 21, 2003
Clinical News

RxKinetix starts Phase II oral mucositis trial

RxKinetix (Louisville, Colo.) started a U.S. Phase II trial of its RK-0202 small molecule antioxidant to treat oral mucositis in 100 patients undergoing radiotherapy for head and neck cancer. The endpoints of the double-blind, placebo-controlled...
BioCentury | Sep 30, 2002
Company News

RxKinetix management update

RxKinetix Inc. , Louisville, Colo. Business: Drug delivery Hired: John Lucas as president and CEO, formerly chairman and CEO of EpiCept Corp. and GmbH WIR Staff...
Items per page:
1 - 10 of 23
BioCentury | Oct 16, 2006
Company News

Endo, RxKinetix deal

...ENDP said its Endo Pharmaceuticals Inc. subsidiary acquired drug delivery company RxKinetix for $20 million in...
...for $20 million in cash and up to $95 million in milestones. The deal includes RxKinetix's...
...severe pain in patients requiring continuous, 24-hour opioid treatment for an extended period of time. RxKinetix...
BioCentury | Mar 6, 2006
Clinical News

RK-0202: Phase II data

...tube compared to placebo (p=0.037). RX-0202 treated patients also had lower incidence of adverse events. RxKinetix Inc....
BioCentury | Mar 6, 2006
Clinical News

RK-0202: Phase III start

...RxKinetix will begin in the second half a double-blind, placebo-controlled Phase III trial. RxKinetix Inc. , Louisville...
BioCentury | Nov 7, 2005
Company News

Indian Immunologicals Ltd., RxKinetix deal

...RxKinetix will formulate using its ProJuvant vaccine delivery technology. Indian Immunologicals Ltd. , Hyderabad, India RxKinetix Inc....
BioCentury | Oct 24, 2005
Clinical News

RK-0202: Preliminary Phase II data

...safety issues, an independent data monitoring committee (IDMC) recommended stopping enrollment earlier in the trial. RxKinetix Inc....
BioCentury | Jun 9, 2003
Company News

Elan, RxKinetix deal

...and develop compound formulations to treat oral mucositis and other oral cavity diseases. As ended, RxKinetix...
...small molecule antioxidant formulated with RxKinetix's ProGelz polymer delivery system, is in Phase II testing. RxKinetix...
...restructuring and focusing on neurology, pain and autoimmune diseases. Elan Corp. plc (ELN), Dublin, Ireland RxKinetix Inc....
BioCentury | Jun 9, 2003
Product Development

Treating the treatments

...Corp. are placing their bets on growth factors to treat mucositis, while others, such as RxKinetix Inc....
...non-systemic approach. "There's absolutely no product out there right now," said Harry Ross, chairman of RxKinetix...
...end or the first quarter of 2004. RK-0202 is a small molecule antioxidant formulated with RxKinetix's...
BioCentury | Jan 27, 2003
Clinical News

RK-0202: Phase II

...placebo-controlled U.S. Phase II trial in 100 patients undergoing radiotherapy for head and neck cancer. RxKinetix Inc....
BioCentury | Jan 21, 2003
Clinical News

RxKinetix starts Phase II oral mucositis trial

RxKinetix (Louisville, Colo.) started a U.S. Phase II trial of its RK-0202 small molecule antioxidant to treat oral mucositis in 100 patients undergoing radiotherapy for head and neck cancer. The endpoints of the double-blind, placebo-controlled...
BioCentury | Sep 30, 2002
Company News

RxKinetix management update

RxKinetix Inc. , Louisville, Colo. Business: Drug delivery Hired: John Lucas as president and CEO, formerly chairman and CEO of EpiCept Corp. and GmbH WIR Staff...
Items per page:
1 - 10 of 23